| Officer | Age | In this role | Joined | 2023 pay | Source |
|---|---|---|---|---|---|
|
Helmy Eltoukhy
Also a director
Chairperson and Co-Chief Executive Officer
|
47 | Not stated | Not stated | $11,591 | |
|
AmirAli Talasaz
Also a director
Co-Chief Executive Officer
|
46 | Not stated | Not stated | $26,415 | |
|
Michael Bell
Chief Financial Officer
|
57 |
Since 2021
5 years
|
Not stated | $4,123,993 | |
|
Darya Chudova
Chief Technology Officer
|
52 |
Since 2023
3 years
|
2015 | $4,755,541 | |
|
Craig Eagle
Chief Medical Officer
|
59 |
Since 2021
5 years
|
Not stated | $3,485,356 | |
|
Christopher Freeman
Chief Commercial Officer
|
52 |
Since 2021
5 years
|
Not stated | $3,523,052 | |
|
Kumud Kalia
Chief Information Officer
|
60 |
Since 2020
6 years
|
Not stated | Not reported | |
|
Terilyn Juarez Monroe
Chief People Officer
|
59 |
Since 2024
2 years
|
Not stated | Not reported | |
|
John Saia
Chief Legal Officer and Corporate Secretary
|
53 |
Since 2022
4 years
|
Not stated | Not reported | |
|
Robert A. Parks
Chief Accounting Officer
Title from the Form 4 dated Nov 9, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Nov 3, 2026
| Director | On board | Independent | Committees | Other public boards | Pay | Source |
|---|---|---|---|---|---|---|
|
Helmy Eltoukhy
Board chair, CEO
|
2013
13 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
AmirAli Talasaz
CEO
|
Not stated | Not independent | None stated | None stated | Paid as CEO | |
|
Ian Clark
Lead independent director
|
2017
9 years
|
Independent |
Governance Committee · Chair
|
Takeda Pharmaceutical Company Limited | $470,242 | |
|
Manuel Hidalgo Medina
|
2024
2 years
|
Independent |
Nominating and Corporate Governance Committee
|
Bristol-Myers Squibb Company | $425,286 | |
|
Alex M. Azar II
|
2025
1 year
|
Independent |
Nominating and Corporate Governance Committee
|
None stated | $725,332 | |
|
Steve Krognes
|
2022
4 years
|
Independent |
Audit Committee · Chair
|
Denali Therapeutics Inc., argenx SE, Pliant Therapeutics, Inc. | $425,286 | |
|
Vijaya Gadde
|
2020
6 years
|
Independent |
Compensation Committee · Chair
|
Planet Labs PBC | $425,286 | |
|
Roberto Mignone
|
2024
2 years
|
Independent |
Audit Committee
|
Teva Pharmaceuticals | $425,286 | |
|
Myrtle Potter
|
2021
5 years
|
Independent |
Audit Committee
|
Opentrons Labworks, Inc. | $425,286 | |
|
Musa Tariq
|
2023
3 years
|
Independent | None stated | None stated | $425,286 | |
|
Kevin R. Sayer
Joined Nov 2, 2026
|
- | - | - | - | - | |
|
Meghan Joyce
Leaving at the meeting
|
Not stated | Independent |
Audit Committee
|
None stated | $425,286 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 28, 2026 states there were none.
Read it in the proxyLoading...